Last reviewed · How we verify
Apomorphine Effect on Pain in Parkinson's Disease: A Randomized, Double-blind Placebo Cross-over Study
To study the effects of acute apomorphine vs. placebo administration on different Parkinson's disease pain types.
Details
| Lead sponsor | University of Calgary |
|---|---|
| Phase | Phase 2/Phase 3 |
| Status | UNKNOWN |
| Enrolment | 40 |
| Start date | 2022-02-28 |
| Completion | 2023-07 |
Conditions
- Parkinson Disease
Interventions
- Apomorphine Injectable Solution
- Placebo
Primary outcomes
- Changes in Unified Parkinson Disease Rating Scale — 0, 1 and 2 weeks
Measures changes of symptom severity, treatment response and the efficacy of treatments. Part 1 (non-motor experiences of daily living), Part 2 (motor experiences of daily living), Part 3 (motor examination) and Part 4 (motor complications). The maximum score for all the parts is 272. Higher scores are indicative of worse outcomes. - Change in Likert Visual Analogue Scale — 0, 1 and 2 weeks
The measure of global pain change perceived by the patients. The most simple Likert Visual Analogue Scale is a straight horizontal line of fixed length, usually 100 mm. The ends are defined as the extreme limits of the parameter to be measured (symptom, pain, health) orientated from the left (worst) to the right (best). There are no numerical values on this scale however, a positioning towards the left of the scale indicates a worse outcome.
Countries
Canada